Connection

Giordano Madeddu to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Giordano Madeddu has written about Drug Therapy, Combination.
Giordano Madeddu
Connection Strength
0.439
Drug Therapy, Combination
  1. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19? Eur Rev Med Pharmacol Sci. 2021 Mar; 25(5):2435-2448.
    View in: PubMed
    Score: 0.327
  2. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
    View in: PubMed
    Score: 0.063
  3. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
    View in: PubMed
    Score: 0.017
  4. Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
    View in: PubMed
    Score: 0.017
  5. Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.